|
KMID : 0378120020290020072
|
|
Chungnam Medical Journal
2002 Volume.29 No. 2 p.72 ~ p.82
|
|
|
Effect of Alendronate for Postmenopausal Osteoporosis according to BMI
|
|
Jo Young-Suk
Na So-Young
Lee Hyo-Jin
Hong Woo-Jeong
Kim Koon-Soon
Kim Do-Hee
Ku Bon-Jeong
Shong Min-Ho
Kim Young-Kun
Ro Heung-Kyu
|
|
|
Abstract
|
|
|
Postmenopausal osteoporosis is a serious health problem. The aminophosphonate Alendronate is widely used for treatment of postmenopausal osteoporosis. We studied the effect of l0㎎ of alendronate given daily for mean 12 months on bone mineral density in 35 women(mean age 61yrs. mean BMI 23.24㎏/m^(2)) with osteoporosis. An over weight group is defined such that BMI was above 23㎏/m^(2). All the women received 1500㎎ calcium carbonate daily. The bone mineral density of L-spine and femoral neck was measured by dual-energy X-ray absorptiometry. Alendronate increased BMD at mean 12 months at the L-spine (7.15±4.5%) and femoral neck(3.05±2.86%) in normal women. Alendronate increased bone mineral density at 12 months at the L-spine(6.00±5.3%) and femoral neck(4.17±4.87%) in overweight women.
There was no difference between two groups. In the less than 7 years group of postmenopausal duration. alendronate increased bone mineral density at 12 months at the L-spine(6.9±4.9%) and femoral neck(3.18±7.1%). In the more than 7 years group of postmenopausal duration, alendronate increased hone mineral density at 1% months at the L-spine(6.5±5.3%) and femoral neck(5.71±0.08%). There was no difference between two groups. In postmenopausal women with osteoporosis, therapy with alendronate produced significant increases in BMD of the L-spine and femoral neck in both group. There was no difference between normal and over-weight groups. and between less than 7 years group and more than 7 years group of postmenopausal duration.
|
|
|
KEYWORD
|
|
|
Postmenopausal osteoporosis, Body mass index, Alendronate
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|